Abbreviated New Drug Application ANDA

When a generic manufacturer completes an Abbreviated New Drug Application (ANDA), the bioequivalency test data are highly likely to be the section... 

Abbreviated New Animal Drug Applications (ANADAs), 21 579 Abbreviated New Drug Application (ANDA) process, 21 575 Abbreviations, l xvii—xxiv 2-26 xv-xxii ABCD fiber categorizing system, 9 199 Abciximab, 4 104t 5 173... 

Form 356h is a harmonized form, and a Sponsor can use it for NDA, BLA, and Abbreviated New Drug Application (ANDA, see Section 8.2.5). Page 1 of the form requires Applicant Information, Product Description, Application Information, and Establishment Information. Page 2 requires the provision of a number of items to substantiate the application. The items to be submitted under Form 356h are as follows ... 

The Hatch-Waxman Act dramatically altered the nature and terms of generic competition after 1984. First, the Act established an Abbreviated New Drug Application (ANDA), which substantially reduced the cost of generic entry. Second, the Act allowed generic manufacturers to conduct their testing prior to patent expiration. This allowed generics to enter the market much more quickly after patent expiration than previously. 

The evidence of formal written procedures is one of the requirements of cGMP as well as the SOP stated in the Abbreviated New Drug Application (ANDA) and (NDA) New Drug Application to ensure compliance to cGMP requirements. 

The references used in the development of abbreviated new drug application (ANDA) file should be cited at the end of the sterility assurance report. 

A comparability protocol may be submitted with a new drug application (NDA), abbreviated new drug application (ANDA), or supplements to these applications. 

This guidance provides recommendations to sponsors of new drug applications (NDA s), abbreviated new drug applications (ANDA s), and abbreviated antibiotic applications (AADA s) who intend, during the postapproval period, to change 1) the components or composition 2) the site of manufacture 3) the scale-up/scale-down of manufacture and/or 4) the manufacturing (process and equipment) of an immediate release oral formulation. 

---